Showing results (51-60 of 140) with videos related to
Sort By:
Pageof 14
Journal of Immunology (Baltimore, Md. : 1950)|May 18, 2012
Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40LMontserrat Cols, Carolina M Barra, Bing He, et al.Cancer|December 20, 2005
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik, Morton Coleman, Lale Kostakoglu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJia Ruan, Peter Martin, Richard R Furman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphomaJohn P Leonard, Morton Coleman, Lale Kostakoglu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.The Journal of Clinical Investigation|December 1, 2015
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient responseCinzia Bologna, Roberta Buonincontri, Sara Serra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2009
Outcome of deferred initial therapy in mantle-cell lymphomaPeter Martin, Amy Chadburn, Paul Christos, et al.Haematologica|January 19, 2023
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergyFrancesca Arruga, Marta Rubin, Despoina Papazoglou, et al.Journal of Hematology & Oncology|June 13, 2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factorsSven de Vos, Andres Forero-Torres, Stephen M Ansell, et al.Blood|January 7, 2018
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapySteven Coutre, Michael Choi, Richard R Furman, et al.Pageof 14